



18, Chemin des Aulx
CH-1228, Plan-Les-Ouates
Switzerland (Geneva)

Geneva, September 8th, 2009

Tel +41 22 794 50 85
Mob +33 679 11 48 27
Mail: hp@geneuro.com
Fax +41 22 880 10 13

United Department of Homeland Security
Citizenship and Immigration Service

Re: Letter of Professional Reference for
CHANTAL DESMOULINS

Dear Sir, Madam,

I am the co-founder of GeNeuro SA, Society for biotechnology, which develops new therapies for pathologies of the nervous system such as multiple sclerosis, schizophrenia, and other serious neurological illnesses.

I first worked at the heart of the bioMerieux Society as director of research on other subjects, such as neuro-degenerative dementia in illnesses such as Creutzfeldt-Jakob disease and Alzheimer's.

I am regularly invited to international conferences on these subjects (you can search for my name on the internet) and am a reviewer for several scientific and medical publications in this field, at the request of the editors of various international journals (Cf. attached CV). I myself have published a number of articles in highly ranked journals, including an article on the discovery of a new non-conventional pathogenic agent published in "The Lancet" (Perron, H., et al. (1991) Isolation of retrovirus from patients with multiple sclerosis. Lancet 337, 862-8). I also identified the molecular sequence of this genome, which was presented by Professor Robert C. Gallo to the National Academy of Sciences (USA) (Perron, H., et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci USA 1997. 94, 7583-7588). I have attached my CV for more details, even though my participation and invitations to numerous conferences have not been recently updated. This information can also be found on the Internet and, if necessary, I can provide an up-to-date schedule through the end of 2009 at your request.

I am currently working on therapeutic trials with the humanized monoclonal antibodies targeting a pathogenic protein identified in the course of my research, following up on the two aforementioned foundational articles on the discoveries that I completed about 20 years ago.

This endogenous protein plays a central and ground breaking role in the pathogenesis, in the chronic persistence of the symptoms, and in the development of neuro-inflammatory illnesses and our therapeutic approach is the goal of the Geneuro society for a first application in the SEO and, thereafter, in other applications including a kind of neurodegenerative inflammation of Schizophrenia (Perron, H. et al. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol Psychiatry 2008. 64, 1019-1023).

Chantal Desmoulins' work was first presented to me in 2006 by Dr. Sergyl Lafont, a medical biologist, and Scientific Watch Director for a large business in the health field.

Dr. Lafont told me of the seriousness of Chantal Desmoulins' research and I agreed to meet with her as she wanted to have practical advice on the methodology of implementing a research project.

The subject was the scientific enhancement of a music-therapy project focused on the Catharsis Technique, of which Chantal is the co-author together with Dr. Alain Amouyal. Dr. Lony Schlitz, clinical psychologist and professor at the Center for Research on Public Health of Luxembourg, was to provide this scientific oversight in preparation for a statistical corroboration that was entrusted to the Department of Applied Mathematics at the University of Luxembourg.

I found that the theoretical foundations laid down by Chantal Desmoulins and Dr. Amouyal over many years brought the seriousness and promise of a rigorous scientific approach to their innovative concept.

So I agreed to take on the role of scientific advisor for this project, as well as any others that Chantal would undertake in the future, in relation to her specialty.

On a personal level, I believe that the Catharsis Technique is one of the high-level music therapy projects that can greatly support other therapies as a complementary treatment, as defined by the OMS. In particular, since it is generally agreed that fundamental reeducation of post-traumatic or other motor deficiencies is indispensable to recuperation and to functional support, it should also make sense that, in the case of "cognitive" deficiencies affecting the higher cerebral functions, a similar "re-education" can also take the form of global stimulation such as is induced by certain music in the cerebral functions affected with Alzheimer's. In effect, these functions cannot rely on the rather limited approaches such as simple re-education of the memory, because the interrelation between the cognitive functions and the functions associated with "feelings" are fundamental since these manage the memory processes through the hippocampus, an area early affected by Alzheimer's. The music can activate these cerebral resources in a unique and original way, within the framework of an indispensable re-education in the therapeutic arsenal for the treatment of this illness.

We need tools and methods that can relieve, in the most subtle ways, the suffering created by these illnesses, for the patients as well as for the families.

That is why I support Chantal Desmoulins in her project to move to the USA. Given my own knowledge of that country, I know that she will find qualified, skilled researchers and investors who will allow her to share the fruits of her magnificent work with the greatest number of people.

Moreover, the music composed by Dr. Alain Amouyal and used in the Catharsis Technique is, for me, very original and has the evocative beauty necessary to stimulate the "emotional" parameters, which other methods do not necessarily possess. As explained above, the stimulation of these parameters is the key to the management of memory by the structures affected in Alzheimer's and, thus, can only be beneficial.

I am sincerely convinced that Chantal Desmoulins' exceptional talent and creativity will find a favorable echo in the United States and will be for the greatest benefit of this beautiful country.

With my most respectful greetings,
Dr. Herve Perron, PhD, HDR
Chief Scientific Officer,
Geneuro SA

